Takeda Pharmaceutical (TAK) Projected to Post Quarterly Earnings on Thursday

Key Points

• Takeda is expected to report Q2 fiscal 2027 results before the market opens Thursday, October 29. Analysts forecast earnings of $0.145 per share on $7.34 billion in revenue.
• In its most recent quarter, Takeda reported $0.95 EPS and $7.50 billion in revenue, exceeding consensus estimates of $0.41 EPS and $7.13 billion in revenue.
• Shares opened at $19.95, near their 52-week high of $20.13, while analyst sentiment stands at a “Moderate Buy”; insiders have sold roughly $11.0 million of stock over the past 90 days.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) is expected to issue its Q2 2027 results before the market opens on Thursday, October 29th. Analysts expect Takeda Pharmaceutical to announce earnings of $0.1450 per share and revenue of $7.34 billion for the quarter. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Parties can check the company's upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 6:00 AM ET.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.95 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.54. The firm had revenue of $7.50 billion during the quarter, compared to analyst estimates of $7.13 billion. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. On average, analysts expect Takeda Pharmaceutical to post $1.56 EPS for the current fiscal year and $1.40 EPS for the next fiscal year.

Takeda Pharmaceutical Stock Down 0.6%

Shares of NYSE:TAK opened at $19.95 on Thursday. Takeda Pharmaceutical has a one year low of $12.99 and a one year high of $20.13. The company has a 50 day moving average of $18.51 and a 200-day moving average of $17.30. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The stock has a market cap of $63.94 billion, a price-to-earnings ratio of 11.95 and a beta of -0.07.

Insiders Place Their Bets

In related news, General Counsel Anne Furney sold 30,868 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $527,842.80. Following the sale, the general counsel owned 204,298 shares of the company's stock, valued at approximately $3,493,495.80. This trade represents a 13.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Andrew Plump sold 116,191 shares of Takeda Pharmaceutical stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $18.49, for a total value of $2,148,371.59. Following the transaction, the insider owned 145,465 shares in the company, valued at approximately $2,689,647.85. This represents a 44.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 627,457 shares of company stock worth $10,981,175 over the last 90 days. 0.04% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on TAK. Weiss Ratings raised shares of Takeda Pharmaceutical from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 8th. Wall Street Zen raised Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research note on Saturday, July 18th. Finally, Zacks Research downgraded Takeda Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 1st. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda's portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.